Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CLpro inhibitors for treating COVID-19
Jianwei Zhang, Yuan Xiong, Feng Wang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 228, pp. 114030-114030
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

The SARS‐CoV‐2 main protease (Mpro): Structure, function, and emerging therapies for COVID‐19
Qing Hu, Yuan Xiong, Guanghao Zhu, et al.
MedComm (2022) Vol. 3, Iss. 3
Open Access | Times Cited: 148
The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022
Xiaojing Pang, Wei Xu, Yang Liu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 257, pp. 115491-115491
Open Access | Times Cited: 63
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review
Xin Li, Yongcheng Song
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115772-115772
Open Access | Times Cited: 52
Advances in the Development of SARS-CoV-2 Mpro Inhibitors
Laura Agost-Beltrán, Sergio de la Hoz‐Rodríguez, Lledó Bou‐Iserte, et al.
Molecules (2022) Vol. 27, Iss. 8, pp. 2523-2523
Open Access | Times Cited: 54
The anti-SARS-CoV-2 activity of novel 9, 10-dihydrophenanthrene derivatives: an insight into molecular docking, ADMET analysis, and molecular dynamics simulation
Imane Yamari, Oussama Abchır, Suraj N. Mali, et al.
Scientific African (2023) Vol. 21, pp. e01754-e01754
Open Access | Times Cited: 40
Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives
Andrea Citarella, Alessandro Dimasi, Davide Moi, et al.
Biomolecules (2023) Vol. 13, Iss. 9, pp. 1339-1339
Open Access | Times Cited: 28
Rational identification of small molecules derived from 9,10-dihydrophenanthrene as potential inhibitors of 3CLpro enzyme for COVID-19 therapy: a computer-aided drug design approach
Ossama Daouı, Souad Elkhattabi, Samir Chtita
Structural Chemistry (2022) Vol. 33, Iss. 5, pp. 1667-1690
Open Access | Times Cited: 31
Identification of new dihydrophenanthrene derivatives as promising anti-SARS-CoV-2 drugs through in silico investigations
Imane Yamari, Oussama Abchır, Hassan Nour, et al.
Main Group Chemistry (2023) Vol. 22, Iss. 3, pp. 469-484
Open Access | Times Cited: 22
Progress in Research on Inhibitors Targeting SARS-CoV-2 Main Protease (Mpro)
Yue Yang, Yidan Luo, Chenbo Zhang, et al.
ACS Omega (2024) Vol. 9, Iss. 32, pp. 34196-34219
Open Access | Times Cited: 6
Discovery of highly potent covalent SARS-CoV-2 3CLpro inhibitors bearing 2-sulfoxyl-1,3,4-oxadiazole scaffold for combating COVID-19
Fu-Mao Zhang, Ting Huang, Feng Wang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115721-115721
Closed Access | Times Cited: 13
Design of Potent Inhibitors Targeting the Main Protease of SARS-CoV-2 Using QSAR Modeling, Molecular Docking, and Molecular Dynamics Simulations
Mehdi Oubahmane, Ismail Hdoufane, Christelle Delaite, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 4, pp. 608-608
Open Access | Times Cited: 11
The crystal structure of 3-amino-2-formyl-1-phenyl-9,10-dihydrophenanthrene-4-carbonitrile, C22H16N2O
Longdie Cheng, Guoyong Luo, Xulan Wang, et al.
Zeitschrift für Kristallographie - New Crystal Structures (2025)
Closed Access
Enantioselective Reductive Cyclization of Alkynyl-Tethered Cyclohexadienones Catalyzed by Rhodium Complexes
Yi-Fan Wang, Feng Wang, Dandan Yang, et al.
Organic Letters (2024) Vol. 26, Iss. 27, pp. 5614-5619
Closed Access | Times Cited: 2
Evaluation of inhibition effect and interaction mechanism of antiviral drugs on main protease of novel coronavirus: Molecular docking and molecular dynamics studies
Xin Gao, Cuihong Wang, Yue Jiang, et al.
Journal of Molecular Graphics and Modelling (2024) Vol. 133, pp. 108873-108873
Closed Access | Times Cited: 2
SAR based Review on Diverse Heterocyclic Compounds with Various Potential Molecular Targets in the Fight against COVID-19: A Medicinal Chemist Perspective
Anish Madan, Mansi Garg, Garvit Satija, et al.
Current Topics in Medicinal Chemistry (2023) Vol. 23, Iss. 14, pp. 1319-1339
Closed Access | Times Cited: 6
Advances in the Developing of SARS-CoV-2 Mpro Inhibitors
Laura Agost-Beltrán, Sergio de la Hoz‐Rodríguez, Lledó Bou‐Iserte, et al.
(2022)
Open Access | Times Cited: 9
Evaluating Z-FA-FMK, a host cathepsin L protease inhibitor, as a potent and broad-spectrum antiviral therapy against SARS-CoV-2 and related coronaviruses
Ju Hwan Jeong, Jang‐Hoon Choi, Beom Kyu Kim, et al.
Antiviral Research (2023) Vol. 216, pp. 105669-105669
Closed Access | Times Cited: 5
One‐step Synthesis of Chiral 9,10‐Dihydrophenanthrenes via Ligand‐enabled Enantioselective Cascade β,γ‐Diarylation of Acids
Tao Sheng, Guowei Kang, Tao Zhang, et al.
Angewandte Chemie International Edition (2024)
Closed Access | Times Cited: 1
Novel Alkynylamide-Based Nonpeptidic Allosteric Inhibitors for SARS-CoV-2 3-Chymotrypsin-like Protease
Jian Xue, Hongtao Li, Ruyu Wang, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 10, pp. 3170-3191
Closed Access | Times Cited: 1
F-CPI: A Multimodal Deep Learning Approach for Predicting Compound Bioactivity Changes Induced by Fluorine Substitution
Qian Zhang, Wenhai Yin, Xinyao Chen, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 1
Acriflavine and proflavine hemisulfate as potential antivirals by targeting Mpro
Jing Liang, Mengzhu Zheng, Wei Xu, et al.
Bioorganic Chemistry (2022) Vol. 129, pp. 106185-106185
Open Access | Times Cited: 7
The potential mechanism of Bletilla striata in the treatment of ulcerative colitis determined through network pharmacology, molecular docking, and in vivo experimental verification
Shanshan Gong, Ronghua Lv, Yihong Fan, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2022) Vol. 396, Iss. 5, pp. 983-1000
Open Access | Times Cited: 7
How many organic small molecules might be used to treat COVID-19? From natural products to synthetic agents
Zai‐Qun Liu
European Journal of Medicinal Chemistry (2024) Vol. 278, pp. 116788-116788
Closed Access | Times Cited: 1
Exploring the structural-activity relationship of hexahydropyrazino[1,2-d]pyrido[3,2-b][1,4]oxazine derivatives as potent and orally-bioavailable PARP7 inhibitors
Silong Zhang, Yu Zhang, Ziwei Wang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115836-115836
Closed Access | Times Cited: 2
Recent progress on drugs discovery study for treatment of COVID-19: repurposing existing drugs and current natural bioactive molecules
Ika Oktavianawati, Mardi Santoso, Mohd Fadzelly Abu Bakar, et al.
Applied Biological Chemistry (2023) Vol. 66, Iss. 1
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top